In summary, high PCSK9 expression in NSCLC tissue was related to a worse response to these treatments, which was also an independent risk factor for both PFS and OS in advanced NSCLC patients with anti-PD-1 immunotherapy. This evidence concerns the gene PCSK9 and non-small cell lung carcinoma.